FOLH1 and prostate cancer: The diagnostic performance of imaging in patients with biochemical recurrence of prostate cancer (BCR) has been substantially improved by positron emission tomography/computed tomography (PET/CT) using radiotracers targeted at prostate-specific membrane antigen (PSMA) [1, 2], a transmembrane glycoprotein overexpressed on the surface of prostate carcincoma cells [3–5].